Exploring delays in primary gynecologic and breast cancer diagnosis after emergency department presentation.
코호트
1/5 보강
[OBJECTIVE] To describe factors influencing endometrial cancer (EC), ovarian cancer (OC), cervical cancer (CC) and breast cancer (BC) diagnosis and intervals (days) to diagnosis following Emergency De
- OR 9.68
- 연구 설계 cohort study
APA
Borkar SR, Tasman JG, et al. (2026). Exploring delays in primary gynecologic and breast cancer diagnosis after emergency department presentation.. Gynecologic oncology, 208, 41-47. https://doi.org/10.1016/j.ygyno.2026.03.005
MLA
Borkar SR, et al.. "Exploring delays in primary gynecologic and breast cancer diagnosis after emergency department presentation.." Gynecologic oncology, vol. 208, 2026, pp. 41-47.
PMID
41861430 ↗
Abstract 한글 요약
[OBJECTIVE] To describe factors influencing endometrial cancer (EC), ovarian cancer (OC), cervical cancer (CC) and breast cancer (BC) diagnosis and intervals (days) to diagnosis following Emergency Department (ED) presentation.
[METHODS] This retrospective cohort study utilized 2015-2021 institutional data and analyzed timing of diagnosis (based on administrative codes) following ED presentation. Zero-inflated negative binomial regression predicted odds of same-encounter diagnosis and, for cases not diagnosed in ED, post-ED interval.
[RESULTS] The study included 642 people assigned female at birth (age > 18 years) with a diagnosis of cancer who had an ED visit within 6 months preceding diagnosis. Median diagnosis intervals (interquartile range) were 25 (4,65) days for EC, 3 (0,17) for OC, 7 (1,62) for CC, and 69.5 (14,124) for BC. Multivariate regression showed OC had highest odds (OR: 9.68, CI: 4.71-19.90) of same-encounter diagnosis compared to BC, with shorter intervals relative to BC for CC (IRR: 0.62, CI: 0.58-0.65), EC (IRR: 0.58, CI: 0.56-0.60), and OC (IRR: 0.35, CI: 0.33-0.36). More comorbidities increased post-ED interval (IRR: 1.09, CI: 1.05-1.10 for 3-4; IRR: 1.15, CI: 1.10-1.20 for >4). PCP access reduced diagnosis during ED-encounter odds (OR: 0.25, CI: 0.15-0.41) and extended post-ED interval (IRR: 1.19, CI: 1.16-1.22).
[CONCLUSION] Gynecologic cancers are more likely to be diagnosed during an ED encounter or within shorter interval after ED-initiated encounter compared to BC. Comorbidities, PCP access, and patient-specific factors-such as insurance and race-significantly influence ED diagnosis likelihood and post-discharge intervals.
[METHODS] This retrospective cohort study utilized 2015-2021 institutional data and analyzed timing of diagnosis (based on administrative codes) following ED presentation. Zero-inflated negative binomial regression predicted odds of same-encounter diagnosis and, for cases not diagnosed in ED, post-ED interval.
[RESULTS] The study included 642 people assigned female at birth (age > 18 years) with a diagnosis of cancer who had an ED visit within 6 months preceding diagnosis. Median diagnosis intervals (interquartile range) were 25 (4,65) days for EC, 3 (0,17) for OC, 7 (1,62) for CC, and 69.5 (14,124) for BC. Multivariate regression showed OC had highest odds (OR: 9.68, CI: 4.71-19.90) of same-encounter diagnosis compared to BC, with shorter intervals relative to BC for CC (IRR: 0.62, CI: 0.58-0.65), EC (IRR: 0.58, CI: 0.56-0.60), and OC (IRR: 0.35, CI: 0.33-0.36). More comorbidities increased post-ED interval (IRR: 1.09, CI: 1.05-1.10 for 3-4; IRR: 1.15, CI: 1.10-1.20 for >4). PCP access reduced diagnosis during ED-encounter odds (OR: 0.25, CI: 0.15-0.41) and extended post-ED interval (IRR: 1.19, CI: 1.16-1.22).
[CONCLUSION] Gynecologic cancers are more likely to be diagnosed during an ED encounter or within shorter interval after ED-initiated encounter compared to BC. Comorbidities, PCP access, and patient-specific factors-such as insurance and race-significantly influence ED diagnosis likelihood and post-discharge intervals.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Early local immune activation following intra-operative radiotherapy in human breast tissue.
- SpNeigh: spatial neighborhood and differential expression analysis for high-resolution spatial transcriptomics.
- Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer Treated With Palbociclib in the POLARIS Study.
- Structural determinants of glycosaminoglycan oligosaccharides as LL-37 inhibitors in breast cancer.
- High accuracy breast cancer classification with BIRADS and coclustering.
- Generational trends in reproductive factors among women in the US: implications for breast cancer incidence.